Chemical Inhibitors Suggest Endophytic Fungal Paclitaxel is Derived from Both Mevalonate and Non-Mevalonate-Like Pathways

Sameh S. M. Soliman,^{§‡} Rong Tsao,[†] and Manish N. Raizada^{*§}

Department of Plant Agriculture, University of Guelph, Guelph, ON Canada N1G 2W1 Department of Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt The Guelph Food Research Centre, Agriculture and Agri-Food Canada, Guelph, ON Canada N1G 5C9

* To whom correspondence should be addressed. Telephone: 1-519-824-4120 x53396. Fax: 1-519-763-8933. E-mail: <u>raizada@uoguelph.ca</u>

[§] Department of Plant Agriculture

[‡]Department of Pharmacognosy

[†] The Guelph Food Research Centre

Figure S1.	Culturing of paclitaxel-producing endophytic fungus.
Figure S2.	Quantification of paclitaxel using a competitive immunoassay with a commercial paclitaxel monoclonal antibody.
Figure S3.	Determination of anti-paclitaxel antibody specificity.
Figure S4.	Quantification of fungal paclitaxel from different fungal parts and ages.
Figure S5.	Effects of solvent system used in this study on fungal metabolism.
Figure S6.	Effects on fungal paclitaxel accumulation of chemical inhibitors previously shown to target enzymes in the MVA and MEP terpenoid precursor or PAL phenolic pathways.
Figure S7.	Sequences of <i>Paraconiothyrium</i> SSM001 genes encoding 3- hydroxymethyl glutyryl CoA synthase (HMGS), and 3- dehydroquinate synthase (DHQS), and fungal <i>Aspergillus</i> gene encoding DXS.
Figure S8.	Determining whether the DXR-like enzyme observed in SSM001 fungus is due to a bacterial endophyte inhabiting the fungus.
Figure S9.	Effects of PAL inhibitor on fungal paclitaxel and fungal phenolics.
Table S1.	Effect of chemical inhibitors on fungal paclitaxel accumulation.
Table S2.	Effect of cinnamic acid on fungal paclitaxel accumulation.



Figure S1. Culturing of paclitaxel-producing endophytic fungus. (A) Two week old pure fungal endophyte culture (SSM001) on PDA media isolated from T. media branches. (B) TLC of chloroform: methanol (9:1) extracts from five different fungal *Paraconiothyrium* SSM001 cultures (lanes 2-6) compared to authentic paclitaxel (lane 1).



Figure S2. Quantification of paclitaxel using a competitive immunoassay with a commercial paclitaxel monoclonal antibody. (A) A schematic representation of the method. The surface of a microtiter plate (M symbol) is coated with the paclitaxel antigen (A triangle) via a protein linker (P circle). In the absence of exogenous paclitaxel, the paclitaxel monoclonal antibody (Ab symbol) binds to the plate-linked paclitaxel. Exogenous paclitaxel (sample) competes with the solid-phase antigen-antibody interaction and is washed away, thus reducing the final colorimetric signal. The solidphase antigen-antibody interaction is detected with a secondary goat antibody linked to alkaline phosphatase enzyme (E symbol) which binds to the primary paclitaxel antibody (Ab symbol). Upon binding of the secondary antibody to the primary antibody, the alkaline phosphatase enzyme (E symbol) is activated, which cleaves the substrate pnitrophenyl phosphate (S symbol), resulting in a yellow colour (C symbol). Exogenous sample paclitaxel thus reduces the vellow colour. (B) Example of the 96-well Paclitaxel competitive colorimetric immunoassay showing a paclitaxel standard curve on the left column, as well as blanks (reagents, but no exogenous paclitaxel) and samples in other rows. A blank corresponds to a yellow well, whereas a well containing a concentrated liquid paclitaxel standard or sample becomes more colourless. (C) Resulting paclitaxel standard curve from the competitive immunoassay demonstrating the linearity of the assay when plotted on a Log scale. The Y-axis (B/Bo) is the mean absorbance for each paclitaxel standard dilution (Abs B) added to non-paclitaxel Fusarium extract divided by the maximum absorbance in the absence of exogenous (aqueous-phase) paclitaxel (Abs Bo). All values were first subtracted from blank wells containing all reagents except exogenous paclitaxel. (D) Example of direct quantification of paclitaxel content (ng/mL) in the liquid cultures of fungus SSM001 at one, two and three week ages using the competitive paclitaxel immunoassay (raw data, diluted).



Figure S3. Determination of anti-paclitaxel antibody specificity. (A-C) Analysis of the sensitivity of the anti-paclitaxel antibody against the taxanes baccatin III and cephalomannine either (A) alone or (B,C) in combination with paclitaxel compared to paclitaxel alone. Shown are the means of three replicates. (D,E) HPLC analysis of (D) three different taxane standards, paclitaxel, baccatin III and cephalomannine, compared to (E) fungal SSM001 extract which showed only one peak corresponding to paclitaxel. This figure indicates that anti-paclitaxel antibody is specific to paclitaxel and not to related taxanes at the relative concentrations expected to occur in the fungal extract.

Supporting Information



Figure S4. Quantification of fungal paclitaxel. (A) TLC of chloroform: methanol (9:1) extracts from different fungal culture samples at different developmental stages. Lane 1: one-week old liquid media fraction; Lane 2: two-week old liquid fraction; Lane 3: threeweek old liquid fraction; Lane 4: paclitaxel standard (black asterisk); Lane 5: three-week old fungal mycelium fraction; Lane 6: two-week old mycelium fraction; Lane 7: oneweek old mycelium fraction. The blue spot in the three-week old culture (liquid media fraction, Lane 3) matched the paclitaxel standard (Lane 4) and with an R_f value (relative to solvent front) of 0.56 and R_{st} value (relative to standard front) of 1.0. The blue spot was not present in any other lanes. (B) Quantification of paclitaxel concentration (µg paclitaxel/g mycelia dry weight, D.W.) in the liquid media fraction compared to mycelia and juice squeezed from the mycelia of fungus SSM001. Paclitaxel quantification was performed using a competitive immunoassay with a commercial paclitaxel monoclonal antibody (see Figure S2 for details). (C) Quantification of paclitaxel concentration (µg/g D.W.) in the liquid cultures of fungus SSM001 at different time points after inoculation. (D) Corresponding quantification of steroids from fungus SSM001 mycelia using the Liebermann-Burchard assay.



Figure S5. Effect of the DMSO: ethanol solvent system used in this study on fungal metabolism, three weeks after inoculation into liquid media cultures. (A) Effect on fungal paclitaxel accumulation [μ g/g Dry Weight (D.W.), competitive immunoassay, liquid media fraction]. (B) Effect on fungal steroid levels (μ g/g D.W., Liebermann-Burchard assay, fungal mycelia fraction). (C) Effect on accumulation of fungal phenolics (μ g/g D.W., p-hydroxybenzaldehyde and Folin-Ciocalteu assay, liquid media fraction).

Supporting Information



Figure S6. Effects on fungal paclitaxel accumulation of chemical inhibitors previously shown to target enzymes in the MVA and MEP terpenoid precursor or PAL phenolic pathways. (A) TLC showing the effects of compactin (mevastatin), a cytosolic MVA pathway inhibitor, and fosmidomycin, a plastid/bacterial MEP pathway inhibitor, on fungal paclitaxel in the liquid media fraction of three-week old fungal cultures. Lane 1: paclitaxel standard; Lane 2: untreated fungus; Lane 3: solvent-treated fungus; Lane 4: compactin at 50 nM, showing the appearance of novel blue spots (black asterisk); Lane 5: compactin at 5.0 nM; Lane 6: fosmidomycin at 3 µM, showing the disappearance of paclitaxel standard-equivalent-blue spot; Lane 7: fosmidomycin at 0.5 µM. (B) TLC showing the effects of cinnamic acid, an inhibitor of phenylalanine ammonia lyase (PAL), critical to the phenylisoserine side chain of plant paclitaxel. Cinnamic acid was applied to three-week old pure liquid cultures of fungal strain SSM001. Lane 1: pooled paclitaxel standard (upper blue spot) and baccatin III standard (Bac III, lower blue spot). Baccatin III is a paclitaxel intermediate in plants which lacks the phenylisoserine side chain; Lane 2: baccatin III standard; Lane 3: cinnamic acid at 1.26 mM, showing a novel blue spot (black asterisk); Lane 4: cinnamic acid at 0.42 mM, showing the partial reappearance of the paclitaxel standard-equivalent blue spot; Lane 5: solvent-treated fungus; Lane 6: untreated fungus.

AspergillusHMGS KPDLTSEYPVVDG-HFSLRCYTEAVDACYKAYNAREKTLKEKV-ONGTNG ArthrodermaHMGS KPDLTSEYPYVDG-HYSTRCYTEAVDACYKAYNAREKVLKG---ONGDSN KPDFTSEYPIVDG-HFSVRCYTEAVDACYKAYNAREETLKS---QQNGAN LeptosphaeriaHMGS PyrenophoraHMGS KPDLTSEYPIVDG-HFSIRCYTEAVDACYKAYNEREKTLKA---OON-GH Paraconiothyrium HMGS LQNSPFEYPVVDGGHFSIRCYTEAVDACYKAYNAREQTLKSQANGSNGVN : . *** *** *:*:******* **:.** AspergillusHMGS TAQDDSKTALDRFDYLCYHAPTC ArthrodermaHMGS GIVDESKTPLDRFDHILFHAPTC LeptosphaeriaHMGS GHAQGQETPLDRFDYMAFHAPTC AVHQDVETPLDRFDYMAFHAPTC PyrenophoraHMGS Paraconiothyrium HMGS GHSQEQETPLDRFDYMCFHAPTC :*.****:: :***** R QMPSKQPISAGIVIVAAGRGERAGSPTEGPKQYRPIG 39 RhizobiumispDF AgrobacteriumDXS QMHSTQPMSIGIVIVAAGRGERAGSPEEGPKQYRAIG 39 SinorhizobiumDXS KMOGEEOFSCGVVIVAAGRGERAGOSAEGPKOYRTIG 60 LAEATTITKIAAVIVAAGRGERAGQSVEGPKQYRRIG 55 OchrobactrumDXS AspergillusDXS MVVSPNPPTIGIVVPAAGRGTRAGQG--CQKAYRRIA 35 . . *: **** * * * RhizobiumispDF GKPVIVHTLENFMTWEPATAIVVVIHPDDEALFAKAFRHIISATPIETVHGGPTRQRSVL 99 AgrobacteriumDXS SinorhizobiumDXS GRPVIAHTLEKFVTWPOTTKIVIVIHRDDEKLLRSAQETIVDSSGVEIAFGGTTROOSVL 99 DRPVIAHTLDIFATWPGAGPVVVVIHPDDEELFAAARKRMAGALELTVVHGGATRQLSVL 120 OchrobactrumDXS GEAVLARTLRVFIDCPLVDSIAVVIHPDDHALYERALP--ENRSNILVVNGGPTRQESTR 113 GDTVINRVLKLFRSWHADCPIVIVHHADDTSLLEASID---RDQKIYTTTGGVERQASVL 92 AspergillusDXS :.:* * ** . .*: :.* : : RhizobiumispDF AGLEYLK--DKHVSHVLIHDAVEPFFDHTLLDEIAENLANG-ALAVLPAMPVTDTLKEAD 156 AGVRQLE--KTGVSHVMIHDAVRPFFDHDLLDRVAAALAAG-APAVLPAMPVTDTLKRAD 156 AgrobacteriumDXS AGLEAVA--ATGVEYVMIHDAVRPFFDHTLLDRCGAALRDG-AQALLPAIAVADTLKRTK 177 LGLRALQ--DSAPQYVMIHDGVRPFVGQDLLKRIVENLAP--DEGVLPALAVSDTLKQSS 169 SinorhizobiumDXS OchrobactrumDXS AspergillusDXS QGLRLLSTLDCVPSHVFIHDAARPFASHALLDSVLESLSTDPSIGVIPAIAVSDTLKKTD 152 .:*:***..*** .: **. . : : * * : . * : * * * * : : *:. : RhizobiumispDF GAGTVLTTVSREQLFAAQTPQSFAFETILDAHEKAAASGRSDFTDDASIAEWLGIPVTIV 216 AgrobacteriumDXS TDALVTETVPRAGLYAAQTPQSFRLADILAAHEKAAADNKTDFTDDAAIAEWAGLPVTLV 216 AAGLVAETVPRTDLYAAQTPQCFRLEPILSAHRRAAASGRSDFTDDASIAEWAGIPVLLV 237 TDGTVKTTVPRAGLFAAQTPQAFPYAPILNAHEKAFAINRSDFTDDAAIAEWQGIAVRII 229 SinorhizobiumDXS OchrobactrumDXS AspergillusDXS SNGLITATVPRDGLFRAQTPQAFEFWSILAAHERAAKSG-SNYTDDASLFEQAGLPVRVV 211 . : ** * *: ** * **.:* . :::****:: *:.* :: RhizobiumispDF EGTGDNVKLTVKKDIAMADDKLSA-----SLLPDVRTGNGYDVHQLEAGDGVTLCGVF 269 AGSADNVKLTIKRDIAMADEKLSA-----GLLPDVRTGNGYDVHQLEPGDGVTLCGVF 269 AgrobacteriumDXS SinorhizobiumDXS EGAVDNFKLTLRRDLSMADEKLTR-----VAIPDVRTGNGYDVHQLVDGDGVTLCGVF 290 EGSADNTKLTWAKDIEMADKRLRQDH----VSFPDIRTGNGYDVHSFEPGDHVTLCGVK 284 OchrobactrumDXS PGDPQNIKLTFSVDFEEAERFLQARNSPIAPPTIPDVRVGHGYDTHRLVPGEGVILCGVK 271 AspergillusDXS :**:*.*:***.* : *: IPHDOKLKGHSDADVALHALTDALLATCGAGDIGDHFPPSDPOWKGAASRIFIEHAARIV 329 RhizobiumispDF AgrobacteriumDXS IPHDQTLKGHSDADVALHALTDALLATCGAGDIGDHFPPSDPQWRGAPSRIFIEHAARIV 329 IPHGRKLSGHSDADVALHALTDALLATCGAGDIGDHFPPSDPQWKGAPSRIFLEHAARIV 350 IPHEAKLNGHSDADVGLHALTDALLATRGAGDIGTHFPPSDPQWKGAASRIFVEHAANIV 344 SinorhizobiumDXS OchrobactrumDXS IPHSASLLGHSDADVGLHALTNAFLGTIGADDIGSHFSPSDPQWKGASSDQFLRHAARLV 331 AspergillusDXS RhizobiumispDF RERGGTIMNADVSLIAEAPKVGPHREAMRANLSEYLGIDLERCSVKATTNETIGFVGRRE 389 RDHGGTIMNADVSLIAEAPKVGPHREAMRAKLSEFLGISLERCSVKATTNEQIGFVGRRE 389 AgrobacteriumDXS SinorhizobiumDXS RERGGTVTNADISLIAEAPKVGPHRQQMRENLAAILGISLDRCSIKATTNEKLGFVGRNE 410 OchrobactrumDXS REAGGRIANVDVTFISEAPKIGPHRIAMTEALCDMLGIAADRVSVKATTNEKLGFVGRRE 404 AspergillusDXS VEAGGTITHCDVSFVCEKPRVSPYRDAMRDSVAGIVGLDRGRVSVKAGTNEKNGFL--IL 389 ** : : *:::.* *::.*:* :. :*: * * • * * * * * RhizobiumispDF GIAAIATATVVYRGRT 405 GIAAIATATVVYRGGR GIAAIATATVVYASRS AgrobacteriumDXS 406 SinorhizobiumDXS 434 OchrobactrumDXS GIAAIATATVIYPGEV 422 AspergillusDXS GLIEIESRKIHYTCRA 449 *: * : .: *

ParaconiothyriumDHQS AspergillusDHQS GlomerellaDHQS PseudonocardiaDHQS CyanotheceDHQS

LHELTPGVPLRHGHAISIDMAYS ATLANGRKLMSDAEHHRILNLFSRAGLSMDHELFNEEI LHELTPPVPLRHGHAISIDMAYS ATLANNRGLLSDDEHRRLLNLFSRAGLSMDHDLFNEEI LHELSPDVPLRHGHAISIDMAFS ATLAHVLGKLSSEEHRRLLNLFSRAGLSMDHPLFDEDM TLELAPPTPMLHGHAIAIDMAFS ATLAARRGDITTGERDRIHRLFSGLGLSVDSTYLTEQI TLELAPRVPMYHGHAVNIDMALS ATLAAKRGYISSTDRDRILGLMSRIGLALDHPLLESÖI **:* .*: ****: **** **::* :: :: *: *:* : .::

Figure S7. Identification of a *Paraconiothyrium* SSM001 gene encoding 3hydroxymethyl glutyryl CoA synthase (HMGS), the enzyme preceding HMGR in the mevalonate pathway, and 3-dehydroquinate synthase (DHQS), a rate-limiting enzyme in the shikimate pathway, and identification of fungal *Aspergillus* DXS, the enzyme preceding DXR, in the bacterial/plant MEP pathway. (A) HMGS sequence similarity with other fungi using Clustal W. (B) Multiple sequence alignments of fungal *Aspergillus* DXS to bacterial and other fungal orthologs using Clustal W. (C) DHQS sequence similarity with other fungi using Clustal W. Highly conserved and similar amino acid residues are shown with an asterisk and dots, respectively.

Figure S7 continued



Figure S8. Determining whether the DXR-like enzyme observed in SSM001 fungus is due to a bacterial endophyte inhabiting the fungus. (A) TLC of SSM001 fungal liquid extract showing effects of chemical inhibitors. Lane 1: paclitaxel standard: Lane 2: 50 nM compactin (mevalonate inhibitor) confirming the disappearance of paclitaxel (blue spot) and the appearance of novel blue spots (black asterisk); Lane 3: 0.7 μ M cycloheximide (eukaryotic cytosolic protein synthesis inhibitor) showing the disappearance of the paclitaxel spot, thus confirming the eukarotic origin of fungal paclitaxel; Lane 4: 0.5 µM cycloheximide; Lane 5: 7.0 nM cycloheximide; Lane 6: 5.0 mM aminooxyacetic acid (AOA, PAL inhibitor) showing that paclitaxel was unaffected; Lane 7: 2 mM AOA; Lane 8: 1.0 mM AOA. (B) Agarose gel electrophoresis to determine if *Paraconiothvrium* SSM001 fungus possesses bacterial endophytes. Shown are products of PCR amplification using primers specific for bacterial and plastidic 16S rDNA. Lanes 1 and 10: DNA marker (100 bp to 10 Kb); Lanes 2 and 5: SSM001 fungal genome template; Lanes 3 and 8: E. coli bacteria DNA template (positive control); Lanes 4 and 7: water template (negative control); Lane 6: fungal liquid media; Lane 9: Taxus plant genome template (positive control). The expected size of the bacterial/plastid 16S rDNA amplicon was 720 bp, equal to the lower band in lanes 3, 8 and 9. The large upper bands in lanes 2 and 5 (from the fungal genome) were cloned and sequenced and were found to be false-positives bearing no significant similarity to bacterial 16S rDNA.



Figure S9. Effects of PAL inhibitor aminooxyacetic acid (AOA) on (A) fungal paclitaxel [µg paclitaxel/gram mycelia dry weight (D.W.), competitive immunoassay, liquid media fraction] and (B) fungal phenolics, calculated as cinnamic acid, a product of PAL in plants (µg/g D.W., P-hydroxybenzaldehyde and Folin-Ciocalteu assay, liquid media fraction).

Chemical inhibitors and	Fungal Dry Weight	Steroid content	Paclitaxel content	Steroid µg/gm	Paclitaxel
concentrations	(DW) g/L	μg/L	μg/L	DW	μg/g DW
Solvent control	11	2.03	80.3332 ± 0.83^1	$0.1846 (100\%)^2$	7.3030(100%) ²
(1 ml DMSO + 4 ml 70%					
ethanol)					
Fosmidomycin 0.5 µM	14	2.35	43.533 ± 0.9	0.16858 (91.3%)	3.109 (42.6%)
Fosmidomycin 1.0 µM	14	1.82	30 ± 0.68	0.1302 (70.5%)	2.142 (29.3%)
Fosmidomycin 3.0 µM	12.2	1.41	0.8666 ± 0.18	0.1157 (62.7%)	0.071 (0.97%)
Compactin (mevastatin)	10.7	0.963	80.333 ± 0.95	0.09042(49.0%)	7.50 (102.7%)
5.0 nM					
Compactin (mevastatin)	11	1.449	0.066 ± 0.008	0.1318 (71.4%)	0.006 (0.08%)
50.0 nM					
Cycloheximide 7.0 nM	8.4	0.450	26.8 ± 0.4	0.05363(29.1%)	3.190 (43.6%)
Cycloheximide 0.5 µM	6.9	0.683	17.7332 ± 0.69	0.0996 (54.0%)	2.57 (35.2%)
a .		0.444	0.6 . 0.00		0.15 (00.40()
Cycloheximide 0.7 µM	4	0.444	8.6 ± 0.88	0.1118 (60.6%)	2.15 (29.4%)
(N-Boc-aminooxy)acetic	10.5	0.884	68.7933 ± 0.65	0.08429(45.7%)	6.551 (89.7%)
acid 1.0 µM					
(N-Boc-aminooxy)acetic	11	0.707	59 ± 0.5	0.06436(34.9%)	5.36 (73.4%)
acid 2.0 µM					
(N-Boc-aminooxy)acetic	10.9	0.834	67.2 ± 0.97	0.0766 (41.5%)	6.165 (84.4%)
acid 5.0 µM					

Table S1 Effect of chemical inhibitors on fungal paclitaxel accumulation.

¹All concentrations were calculated as an average of three experiments and \pm stands for the standard error of the mean.

²Bracket notes percentage relative to solvent control.

Chemical inhibitors and	Fungal Dry Weight (DW)	Paclitaxel content	Paclitaxel
concentrations	g/L	μg/L	μg/g DW
Solvent control	12.4	193.44 ± 1.32^{1}	$15.60 (100\%)^2$
(1 ml DMSO + 4 ml 70% ethanol)			
dl-Cinnamic acid 0.42 mM	15.86	10.35 ± 0.46	0.66 (4.23%)
dl-Cinnamic acid 1.26 mM	14.378	0.151 ± 1.10	0.01 (0.064%)

Table S2 Effect of cinnamic acid on fungal paclitaxel accumulation.

¹All concentrations were calculated as an average of three experiments and \pm stands for the standard error of the mean.

²Bracket notes percentage relative to solvent control.